Phase II trial of interleukin-12 (NSC #672423, IND #6798) followed by interferon alfa-2B in patients with metastatic malignant melanoma

Trial Profile

Phase II trial of interleukin-12 (NSC #672423, IND #6798) followed by interferon alfa-2B in patients with metastatic malignant melanoma

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Dec 2012

At a glance

  • Drugs Interferon alpha (Primary) ; Interleukin-12 (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Apr 2011 Actual end date changed from Jan 2010 to Feb 2008 as reported by ClinicalTrials.gov.
    • 01 Apr 2011 Actual initiation date changed from Jun 2002 to Sep 2001 as reported by ClinicalTrials.gov.
    • 24 Mar 2010 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top